The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels | BMC Cancer | Full Text

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels | BMC Cancer | Full Text

BMC Cancer

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

• Gustavo WerutskyEmail author,
• Fernando Cotait Maluf,
• Eduardo Henrique Cronemberger,
• Vinicius Carrera Souza,
• Suelen Patricia dos Santos Martins,
• Fábio Peixoto,
• Oren Smaletz,
• Fábio Schutz,
• Daniel Herchenhorn,
• Telma Santos,
• Flavio Mavignier Carcano,
• David Queiroz Muniz,
• Paulo R. S. Nunes Filho,
• Facundo Zaffaroni,
• Carlos Barrios and
• André Fay

BMC Cancer201919:487

https://doi.org/10.1186/s12885-019-5709-y

©  The Author(s). 2019

• Received: 5 May 2018
• Accepted: 14 May 2019
• Published: 23 May 2019

Open Peer Review reports

Abstract

Background

Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate with prednisone (AAP) and apalutamide, alone or in combination, can be an effective hormonal therapy also possibly decreasing castration-associated side effects.

Methods

Phase II, open-label, randomized, efficacy trial of abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT) versus apalutamide versus the combination of AAP (without ADT) and apalutamide. Key eligibility criteria are confirmed prostate adenocarcinoma; biochemical relapse after definitive treatment (PSA ≥ 4 ng/ml and doubling time less than 10 months, or PSA ≥ 20 ng/ml); newly diagnosed locally advanced or metastatic prostate cancer; asymptomatic to moderately symptomatic regarding bone symptoms. Patients with other histology besides adenocarcinoma or previous use of hormonal therapy or chemotherapy were excluded.

Discussion

There is an urgent need to study and validate regimens such as new hormonal agents that may add benefit to castration with an acceptable safety profile. We aim to evaluate if apalutamide in monotherapy or in combination with AAP is an effective and safety hormonal treatment that can spare patients of androgen deprivation therapy.

Trial registration

This trial was registered in ClinicalTrials.gov on October 16, 2017, under Identifier: NCT02867020.

Keywords

• Castration-sensitive prostate cancer
• Hormonal therapy
• Androgen deprivation therapy
• Abiraterone
• Apalutamide
• Goserelin